Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations

European Journal of Human Genetics

Volumn 16, Issue 12, 2008, Pages 1487-1498

  Tabolacci, Elisabetta ^a   Moscato, Umberto ^a   Zalfa, Francesca ^b   Bagni, Claudia ^b,c   Chiurazzi, Pietro ^a   Neri, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; HISTONE H3; HISTONE H4; LYSINE; MESSENGER RNA;

ACETYLATION; ADULT; ALLELE; ARTICLE; CASE REPORT; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CPG ISLAND; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; EUCHROMATIN; FIBROBLAST; FRAGILE X SYNDROME; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INACTIVATION; GENE MUTATION; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MALE; MENTAL DEFICIENCY; MOSAICISM; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RNA TRANSLATION;

CELL LINE; CELLS, CULTURED; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; EUCHROMATIN; FAMILY; FEMALE; FIBROBLASTS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MALE; MODELS, BIOLOGICAL; MUTATION;

EID: 56749106679     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2008.130     Document Type: Article

References (48)

1. Verkerk AJ, Pieretti M, Sutcliffe JS et al: Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65: 905-914.
2. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D et al: Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X Study: Preliminary data. Am J Med Genet 1999; 83: 322-325.
3. Hagerman RJ, Leehey M, Heinrichs W et al: Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57: 127-130.
4. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ: Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in the fragile X syndrome. Am J Hum Genet 2000; 66 6-15.
5. Oberle' I, Rousseau F, Heitz D et al: Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 1991; 252: 1097-1102.
6. Pieretti M, Zhang F, Fu YH et al: Absence of expression of the FMR1 gene in fragile X syndrome. Cell 1991; 66: 817-822.
7. Sutcliffe JS, Nelson DL, Zhang F et al: DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet 1992; 1: 397-400.
8. Bestor TH: The DNA methyltransferases of mammals. Hum Mol Genet 2000; 9: 2395-2402.
9. Kress C, Thomassin H, Grange T: Local DNA demethylation in vertebrates: how could it be performed and targeted? FEBS Lett 2001; 494: 135-140.
10. Lee KK, Workman JL: Histone aceOyltransferase complexes: one size doesn't fit all. Nat Rev Mol Cell Biol 2007; 8: 284-295.
11. Yang XJ, SFto E: HATs and HDACs: from structure, function and regulation to novel strategies tor therapy and prevention. Oncogene 2007; 26: 5310-5318.
12. Yang XJ, Seto E: Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev 2003; 13: 143-153.
13. Zaratiegui M, Irvine DV, Martienssen RA: Noncoding RNAs and gene silencing. Cell 2007; 128: 763-776.
14. Lachner M, O'Sullivan RJ, Jenuwein T. An epigenetic road map for histone lysine methylation. J Cell Sci 2003; 116: 2117-2124.
15. Shi Y: Histone lysine dEmethylases: emerging roles in development, physiology and disease. Nat Rev 2007; 8: 829-833.
16. Shi Y, Whetstine JR: Dynamic regulation of histone lysine methylation by demethylases. Mol Cell 2007; 25: 1-14.
17. Nishioka K, Chuikov S, Sarma K et al: Set9, a novel histone H3 ethyltransferase that facilitates transcription by precluding histone tail modifications require for heterochromatin formation. Genes Dev 2002; 16: 479-489.
18. Li E: Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002; 3: 662-673.
19. Grewal SIS, Moazed D: Heterochromatin and epigenetic control of gene expression. Science 2003; 301: 798-802.
20. Vakoc CR, Mandat SA, Olenchock BA, Blobel GA: Histone H3 lysine 9 methylation and HP1y are associated with transcription elongation through mammalian chromatin. Mol Cell 2005; 19: 381-391.
21. Yasuhara JC,TWakimoto BT: Oxymoron no more: the expanding world of heterochromatic genes. Trends Genet 2006; 22: 330-338.
22. Matzke MA, Birchler JA: RNAi-mediated pathways in the nucleus. Nature Rev Genet 2005; 6: 24-35.
23. Sparmann A, van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nature Rev Cancer 2006; 6: 846-856.
24. Lee MG, Villa R, Trojer P et al: Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 2007; 318 447-450.
25. Coffee B, Zhang F, Warren S, Reines D: Acetylated histones are associated with FMR1 in normal but not fragile X syndrome cells. Nature Genet 1999; 22: 98-101.
26. Coffee B, Zhang F, Ceman S, Warren S, Reines D: Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile X syndrome. Am J Hum Genet 2002; 71: 923-932.
27. Pietrobono R, Tabolacci E, Zalfa F et al: Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet 2005; 14: 267-277.
28. Chiurazzi P, Pomponi MG, Pletrobono R, Bakker CE, Neri G, Oostra BA: Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet 1999; 8 2317-2323.
29. Smeets HJ, Smits AP, Verheij CE et al: Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet 1995; 4 2103-2108.
30. Brouwer JR, Mientjesa EJ, Bakker CE et al: Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res 2007; 313 244-253.
31. Eiges R, Urbach A, Malcov M et al: Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 2007; 1: 568-577.
32. Tabolacci E, Pietrobono R, Moscato U, Oostra BA, Chiurazzi P, Neri G: Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet 2005; 13: 641-648.
33. Pietrobono R, Pomponi MG, Tabolacci E, Oostra BA, Chiurazzi P, Neri G: Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res 2002; 30: 3278-3285.
34. Tabolacci E, Pomponi MG, Pietrobono R, Chiurazzi P, Neri G: A unique case of reversion to normal size of a maternal premutation FMR1 allele in a normal boy. Eur J Hum Genet 2007; 16: 209-214.
35. Wohrle D, Salat U, Hameister H, Vogel W, Steinbach P: Demethylation reactivation, and destabilization of human fragile X full mutation alleles in mouse embryocarcinoma cells. Am J Hum Genet 2001; 69 504-515.
36. Tassone F, Hagerman RJ, Loesch DZ, Lachiewicz A, Taylor AK, Hagerman PJ: Fragile X males with unmethylated full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet 2000; 94: 232-236.
37. Feng Y, Zhang F, Lokey LK et al: Translational suppression by trinucleotide repeat expansion at FMR1. Science 1995; 268: 731-734.
38. Tassone F, Hagerman RJ, Taylor AK et al: Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000; 91: 144-152.
39. n destabilizing proteins hnRNP A2 and CBF-A enhance the in vivo translation of fragile X premutation mRNA. Nucleic Acids Res 2007; 35: 5775-5788.
40. Taylor AK, Tassone F, Dyer PN et al: Tissue heterogeneity of the FMR1 mutation in a high-functioning male with Fragile X syndrome. Am J Med Genet 1999; 84: 233-239.
41. Litt MD, Simpson M, Gaszner M, Allis CD, Felsenfeld G: Correlation between histone lysine methylation and development changes at the chicken beta-globin locus. Science 2001; 293: 2453-2455.
42. Zofall M, Grewal SI: Swi6/HP1 recruits a JmjC domain protein to facilitate transcription of heterochromatic repeats. Mol Cell 2006; 22: 681-692.
43. Grewal SIS, Jia S: Heterochromatin revisited. Nat Rev 2007; 8 35-46.
44. Fuks F, Hurd PJ, Wold D, Nan X, Bird AP, Kouzarides T: The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003; 278: 4035-4040.
45. Motamedi MR, Verdel A, Colmenares SU, Gerber SA, Gygi SP, Moazed D: Two RNAi complexes, RITS and RDRC, physically interact and localize to noncoding centromeric RNAs. Cell 2004; 119: 789-802.
46. Handa V, Saha T, Usdin K: The fragile X syndrome repeats form RNA hairpins that do not activate the interferon-inducible protein kinase, PKR, but are cut by Dicer. Nucleic Acids Res 2003; 31: 6243-6248.
47. Hong EE, Villen J, Gerace EL, Gygi SP, Moazed DA: Cullin E3 ubiquitin ligase complex associates with Rik1 and the Clr4 histone H3-K9 methyltransferase and is required for RNAi-mediated heterochromatin formation. RNA Biol 2005; 2: 106-111.
48. Cao R, Wang L, Wang H et al: Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 2002; 298: 1039-1043.